跳至主要内容
临床试验/2025-521163-12-01
2025-521163-12-01招募中2 期

The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年10月30日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
10
试验地点
1
主要终点
FAPI uptake in active GO versus inactive GO on PET-MRI

研究概览

简要总结

The main objective of this study is to compare the uptake of FAPI (Fibroblast Activation Protein Inhibitor) in patients with active Graves' Ophthalmopathy (GO) versus those with inactive GO. This comparison aims to determine the differential uptake patterns and potential diagnostic value of FAPI in assessing disease activity in GO patients.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Inclusion of 5 patients with Graves Orbitopathy (GO) and Clinical Activity Score (CAS) >3, consistent with active GO.
  • Inclusion of 5 patients with GO who have previously undergone CAS >3, but with a current low CAS of 0 or 1 for at least 6 months (i.e. inactive GO)

排除标准

  • General exclusion criteria for MRI, including (but not limited to) claustrophobia, metal-splinters in face-area, recent surgery etc.
  • For active GO: if PET-MRI can not be performed <14 days, patient will not be included

结局指标

主要结局

FAPI uptake in active GO versus inactive GO on PET-MRI

FAPI uptake in active GO versus inactive GO on PET-MRI

次要结局

  • Relation MRI results (edema), clinical symptoms, and lab values to FAPI-uptake on PET.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Department of Radiology and Nuclear Medicine

Scientific

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

研究点 (1)

Loading locations...

相似试验